Literature DB >> 18095072

A significant improvement in lower limb pain after treatment with alendronate in two cases of Camurati-Engelmann disease.

Kousuke Iba1, Junichi Takada, Hotaka Kamasaki, Takashi Oda, Naoko Hatakeyama, Takuro Wada, Toshihiko Yamashita.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18095072     DOI： 10.1007/s00774-007-0783-7

Source DB:  PubMed          Journal:  J Bone Miner Metab        ISSN： 0914-8779            Impact factor:   2.626


× No keyword cloud information.
  14 in total

1.  Pamidronate in the treatment of progressive diaphyseal dysplasia (Camurati-Engelmann disease)

Authors:  G Chérié-Lignière; G Santalena; A Parafioriti
Journal:  Clin Exp Rheumatol       Date:  1999 Mar-Apr       Impact factor: 4.473

2.  Camurati-Engelmann disease: failure of response to bisphosphonates: report of two cases.

Authors:  Glaucio R W Castro; Simone Appenzeller; João Francisco Marques-Neto; Manoel B Bértolo; Adil M Samara; Ibsen Coimbra
Journal:  Clin Rheumatol       Date:  2005-01-20       Impact factor: 2.980

3.  Biochemical markers of bone turnover in Camurati-Engelmann disease: a report on four cases in one family.

Authors:  M V Hernández; P Peris; N Guañabens; L Alvarez; A Monegal; F Pons; A Ponce; J Muñoz-Gómez
Journal:  Calcif Tissue Int       Date:  1997-07       Impact factor: 4.333

4.  Progessive diaphyseal dysplasia. Review of the literature and report of seven cases in one family.

Authors:  J D Hundley; F C Wilson
Journal:  J Bone Joint Surg Am       Date:  1973-04       Impact factor: 5.284

5.  Domain-specific mutations in TGFB1 result in Camurati-Engelmann disease.

Authors:  A Kinoshita; T Saito; H Tomita; Y Makita; K Yoshida; M Ghadami; K Yamada; S Kondo; S Ikegawa; G Nishimura; Y Fukushima; T Nakagomi; H Saito; T Sugimoto; M Kamegaya; K Hisa; J C Murray; N Taniguchi; N Niikawa; K Yoshiura
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

6.  Scintigraphic evaluation of pamidronate and corticosteroid therapy in a patient with progressive diaphyseal dysplasia (Camurati-Engelmann disease).

Authors:  T Inaoka; N Shuke; J Sato; Y Ishikawa; K Takahashi; T Aburano; Y Makita
Journal:  Clin Nucl Med       Date:  2001-08       Impact factor: 7.794

7.  Osteoclasts play a part in pain due to the inflammation adjacent to bone.

Authors:  Maho Nagae; Toru Hiraga; Hiroki Wakabayashi; Liyang Wang; Koichi Iwata; Toshiyuki Yoneda
Journal:  Bone       Date:  2006-11       Impact factor: 4.398

8.  Progressive diaphyseal dysplasia (Camurati-Engelmann's disease). Improvement of clinical signs and of bone scintigraphy during pregnancy.

Authors:  A De Vits; B Keymeulen; A Bossuyt; G Somers; L A Verbruggen
Journal:  Clin Nucl Med       Date:  1994-02       Impact factor: 7.794

9.  Correlation between bone imaging and the clinical picture in two unsuspected cases of progressive diaphyseal dysplasia (Engelmann's disease).

Authors:  A D'Addabbo; L Macarini; G Rubini; D Rubini; F Salzillo; F Lauriero
Journal:  Clin Nucl Med       Date:  1993-04       Impact factor: 7.794

10.  Progressive diaphyseal dysplasia (Camurati-Engelmann): radiographic follow-up and CT findings.

Authors:  J K Kaftori; U Kleinhaus; Y Naveh
Journal:  Radiology       Date:  1987-09       Impact factor: 11.105
View more
  7 in total

1.  Pain improvement in Camurati-Engelmann disease after anti-TNFα therapy.

Authors:  Sónia Moreira; Bernardo Cunha; Nelson Pedro Jesus; Lèlita Santos
Journal:  BMJ Case Rep       Date:  2017-11-28

2.  Significant Improvement of Clinical Symptoms, Bone Lesions, and Bone Turnover after Long-Term Zoledronic Acid Treatment in Patients with a Severe Form of Camurati-Engelmann Disease.

Authors:  Giampiero I Baroncelli; Elena Ferretti; Cecilia M Pini; Benedetta Toschi; Rita Consolini; Silvano Bertelloni
Journal:  Mol Syndromol       Date:  2017-09-09

Review 3.  Improvement of Bone Health and Initiation of Puberty Development in Camurati-Engelmann Disease With Glucocorticoid and Losartan Treatment: A Case Report and Review of Literature.

Authors:  Lijia Cui; Qian Li; Wenmin Guan; Wei Yu; Xiang Li; Weibo Xia; Yan Jiang
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-17       Impact factor: 6.055

Review 4.  Significant Improvement After Surgery for a Symptomatic Osteoblastoma in a Patient with Camurati-Engelmann Disease: Case Report and Literature Review.

Authors:  Hirotaka Yonezawa; Katsuhiro Hayashi; Norio Yamamoto; Akihiko Takeuchi; Kaoru Tada; Shinji Miwa; Kentaro Igarashi; Hiroaki Kimura; Yu Aoki; Sei Morinaga; Yoshihiro Araki; Yohei Asano; Keisuke Sakurakichi; Hiroko Ikeda; Takayuki Nojima; Hiroyuki Tsuchiya
Journal:  Calcif Tissue Int       Date:  2021-02-08       Impact factor: 4.333

5.  Camurati-Engelmann disease: unique variant featuring a novel mutation in TGFβ1 encoding transforming growth factor beta 1 and a missense change in TNFSF11 encoding RANK ligand.

Authors:  Michael P Whyte; William G Totty; Deborah V Novack; Xiafang Zhang; Deborah Wenkert; Steven Mumm
Journal:  J Bone Miner Res       Date:  2011-05       Impact factor: 6.741

6.  Camurati-Engelmann Disease Complicated by Hypopituitarism: Management Challenges and Literature Review of Outcomes With Bisphosphonates.

Authors:  Liza Das; Vandana Dhiman; Pinaki Dutta; Ashwani Sood; Mahesh Prakash; Simran Kaur; Ellen Steenackers; Gretl Hendrickx; Devi Dayal; Wim Van Hul; Sanjay Kumar Bhadada
Journal:  AACE Clin Case Rep       Date:  2021-10-20

7.  Clinical characteristics and identification of a novel TGFB1 variant in three unrelated Chinese families with Camurati-Engelmann disease.

Authors:  Xiao-Hui Tao; Xing-Guang Yang; Zi-Yuan Wang; Yang Xu; Xiao-Yun Lin; Tian Xu; Zhen-Lin Zhang; Hua Yue
Journal:  Mol Genet Genomic Med       Date:  2022-03-21       Impact factor: 2.473
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.